Sinopharm Group (SHTDY) Fair Value & Analysis
Healthcare · US · Market cap $6.6B
Sinopharm Group
SHTDY · US
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from $83.93 to $28.00 (−66.6%) since Jun 24, 2026. Share price −3.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $10.05 – $14.07 · fair‑value band $21.00 – $35.00 · the $10.50 price screens below the $28.00 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sinopharm Group (SHTDY) currently trades at $10.50, while our model-based Fair Value estimate is $28.00 — implying the stock looks roughly 166.7% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Sinopharm Group generated revenue of $574B at a net margin of 1.2%. Revenue declined 0.6% year over year. It earns a return on equity of 8.1%. Net debt stands at $47.1B. Fundamentals as of Jul 5, 2026
Our scenario range runs from $21.00 (bear case) to $35.00 (bull case); at $10.50, the current price sits below that range. The share trades about 29% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside — at 167%, SHTDY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sinopharm Group reported revenue of $559B in FY2025 versus $521B in FY2021, a compound +1.8%/yr. Reported net income was $7.0B in FY2025, compounding −2.7%/yr from FY2021.
Is SHTDY fairly valued? → Check now
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$1,022 | R$1,243 | +22% |
| Cencora, Inc C1CO34 | R$707.04 | R$79.88 | -89% |
| Cardinal Health, Inc CAH | $216.30 | $110.75 | -49% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.6300 | -73% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.34 | ¥34.72 | +112% |
| Henry Schein, Inc HSIC | $78.67 | $67.77 | -14% |
| Galenica AG GALNF | $115.00 | $84.59 | -26% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥20.81 | ¥25.18 | +21% |
| Medipal Holdings MEPDF | $18.35 | $25.47 | +39% |
| Jointown Pharmaceutical Group 600998 | ¥4.87 | ¥9.24 | +90% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sinopharm Group (SHTDY) undervalued?
What is the fair value of SHTDY?
What is the quality score of SHTDY?
What is the revenue of Sinopharm Group (SHTDY)?
What is the net profit margin of SHTDY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.